Tentative guidelines and practical suggestions to avoid venous thromboembolism during oral contraceptive therapy

Clinical and Applied Thrombosis/Hemostasis

Volumn 8, Issue 2, 2002, Pages 97-102

  Girolami, Antonio ^a   Spiezia, L ^a   Girolami, B ^a   Vianello, F ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Oral contraceptives; Venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; DESOGESTREL; ETHINYLESTRADIOL; GESTODENE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE; PROTEIN C; PROTEIN S; PROTHROMBIN; STEROID;

ANAMNESIS; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BLOOD PRESSURE; DEHYDRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; FIBRINOGEN DEFECT; FIBRINOLYSIS; HEMATOCRIT; HOMOZYGOSITY; HUMAN; HYPERTENSION; IMMOBILIZATION; LABORATORY TEST; LIVER FUNCTION TEST; LIVER INJURY; OBESITY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTHROMBIN DEFICIENCY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; SPLINT; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; VEIN THROMBOSIS; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG CONTRAINDICATION;

CONTRACEPTIVES, ORAL; FEMALE; HUMANS; PRACTICE GUIDELINES; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0035992571     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960200800204     Document Type: Review

References (36)

1. Oral contraceptives and venous thromboembolism: Finding in a large prospective study
2. Venous thromboembolism in relation to oral contraceptive use
3. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study
4. Oral contraceptives and the risk of venous thrombosis
5. The role of drugs, particularly oral contraceptives in triggering thrombosis in congenital defects of coagulation inhibitors: A study of six patients
6. Bilateral ileo-femoral thrombophlebitis after ten contraceptive pills in a 25-year-old woman with antithrombin III deficiency
7. Oral contraceptives caused thrombosis in a monoovular twin protein C deficiency, while the other, without medication, remained asymptomatic
8. Patient with APC-resistance as compared with other clotting inhibitor deficiencies show a later onset of venous thrombosis during oral contraception
9. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
10. Combined oral contraceptives containing desogestrel or gestodene and the risk of venous thromboembolism
11. Oral contraceptives and cardiovascular disease (first of two parts)
12. Blood coagulation and oral contraceptives. A critical review
13. Homozygous patients with APC resistance may remain paucisymptomatic or asymptomatic during oral contraception
14. APC resistance, oral contraceptive therapy and deep vein thrombosis: Settled and unsettled problems
15. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: A prospective cohort study
16. Prothrombotic activity of oral contraceptives in patients with congenital thrombophilia varies with the defect
17. Prolonged oral contraceptive therapy in a woman with an antithrombin III abnormality involving heparin binding (type IIc) without thromboembolic complications
18. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis
19. Long-term use of oral contraceptive therapy in women with the prothrombin 20210 g-a polymorphism without thrombotic complications: A study of 13 women (12 heterozygotes and 1 homozygote)
20. Newer oral contraceptives and the risk of venous thromboembolism
21. Risk of idiopathic cardiovascular death and nonfatal venous, thromboembolism in women using oral contraceptives with differing progestagen components
22. Risk of venous thromboembolism with third-generation oral contraceptives: A review
23. Cardiovascular disease and combined oral contraceptives: Reviewing the evidence and balancing the risks
24. Third generation oral contraceptives
25. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study
26. Population-based study of risk of venous, thromboembolism associated with various oral contraceptives
27. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: Analysis of general practice research database
28. First-time use of newer oral contraceptives and the risk of venous thromboembolism
29. Oral contraceptives and thrombotic disease: Risk of venous thromboembolism
30. Rebuttal to: Oral contraceptives and venous thromboembolism
31. Hormonal contraception and risk of cardiovascular disease. An international perspective
32. The third generation oral contraceptive controversy. The evidence shows they are less safe than second generation pills
33. Using epidemiological data to guide clinical practice: Review of studies on cardiovascular disease and use of combined oral contraceptives
34. Renewed interest in haemostasis changes induced by oral contraceptives (OCs)
35. The long-term clinical course of acute deep venous thrombosis
36. The natural history and epidemiology of venous thrombosis